Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Sharon O'Byrne"'
Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
Autor:
Rebecca Curtis, Parnia Geransar, Arpeat Kaviya, Sharon O'Byrne, Stefan Schreiber, Javaria Mona Khalid, Bernd Bokemeyer, Alexandra James, Robert Ehehalt, Douglas C. Wolf, Andreas Stallmach, Brian G. Feagan, Jeffrey Axler
Publikováno v:
Inflammatory Bowel Diseases
Background Sustaining clinical remission is an important treatment goal in moderate-to-severe UC. This post hoc exploratory analysis assessed the long-term efficacy of vedolizumab in the subset of patients with UC in the GEMINI 1 study who were in cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c0dc1d9979c3e7d8b4be4fec2eebd8b
https://doi.org/10.1093/ibd/izy323
https://doi.org/10.1093/ibd/izy323
Publikováno v:
Journal of Crohn's and Colitis. 12:S653-S668
Integrins are cell surface receptors with bidirectional signalling capabilities that can bind to adhesion molecules in order to mediate homing of leukocytes to peripheral tissues. Gut-selective leukocyte homing is facilitated by interactions between
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b308326247b30d1b1eb807ca31114aea
https://doi.org/10.1093/ecco-jcc/jjy060
https://doi.org/10.1093/ecco-jcc/jjy060
Autor:
Sharon O'Byrne, Leonid Gibiansky, Yehong Wang, Xiaohui Wei, Franklin Fuh, Rich Erickson, Meina T. Tang
Publikováno v:
Journal of Clinical Pharmacology
Etrolizumab, a humanized monoclonal antibody, specifically binds to the β7 subunit of the heterodimeric integrins α4β7 and αEβ7. Pharmacokinetic (PK) and pharmacodynamic (PD) data were collected from an etrolizumab phase 1 trial in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66d4af8790d77063fcec4dd624bda2b4
http://europepmc.org/articles/PMC5836964
http://europepmc.org/articles/PMC5836964
Autor:
Javaria Mona Khalid, W J Sandborn, Parnia Geransar, Nigel Brayshaw, J.-F. Colombel, Brian G. Feagan, Sharon O'Byrne, David T. Rubin
Publikováno v:
Journal of Crohn's and Colitis. 11:S36-S38
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0497dad712d8ca03acc41080b4b2689
https://doi.org/10.1093/ecco-jcc/jjx002.056
https://doi.org/10.1093/ecco-jcc/jjx002.056
Autor:
Christopher A, Lamb, John C, Mansfield, Gaik W, Tew, Deena, Gibbons, Anna K, Long, Peter, Irving, Lauri, Diehl, Jeff, Eastham-Anderson, Maria B, Price, Graeme, O'Boyle, David E J, Jones, Sharon, O'Byrne, Adrian, Hayday, Mary E, Keir, Jackson G, Egen, John A, Kirby
Publikováno v:
Journal of Crohn's & Colitis
Background and Aims: The αEβ7 integrin is crucial for retention of T lymphocytes at mucosal surfaces through its interaction with E-cadherin. Pathogenic or protective functions of these cells during human intestinal inflammation, such as ulcerative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fb4b095bc702ac7884b1ad026358c692
https://pubmed.ncbi.nlm.nih.gov/28453768
https://pubmed.ncbi.nlm.nih.gov/28453768
Publikováno v:
Journal of Crohn'scolitis. 10
Ulcerative colitis and Crohn's disease have traditionally been managed by incrementally stepping up within a hierarchy of therapeutic classes consequent to failing a given therapeutic─necessitated by the notion that any type of therapeutic will onl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a4fc97efc01b0127ea6e76caf13919e
https://pubmed.ncbi.nlm.nih.gov/27302971
https://pubmed.ncbi.nlm.nih.gov/27302971
Autor:
Brian G. Feagan, Silvio Danese, Alexandra James, G. D'Haens, I. Shafran, Parnia Geransar, David T. Rubin, J.-F. Colombel, W J Sandborn, Bruce E. Sands, Severine Vermeire, Arthur Kaser, Sharon O'Byrne, Javaria Mona Khalid, Edward V. Loftus, Remo Panaccione, Arpeat Kaviya
Publikováno v:
Journal of Crohn's and Colitis. 11:S182-S183
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebba1a64355db8e5b47a4bbcf846a6bd
https://doi.org/10.1093/ecco-jcc/jjx002.334
https://doi.org/10.1093/ecco-jcc/jjx002.334
Autor:
S Fong, Cary M. Looney, Sinisa Ivelja, Olivia Hwang, Tom Gelzleichter, Rich Erickson, V Albert, Kathy Howell, Suhasini Iyer, Mercedesz Balazs, Surinder Jeet, Henry Chiu, Eric Stefanich, Hong Wang, Hajime Hiraragi, Marna Williams, Sharon O'Byrne, Franklin Fuh, Shweta Gadkari, Dimitry M. Danilenko, Canio J. Refino
Publikováno v:
British Journal of Pharmacology. 162:1855-1870
BACKGROUND AND PURPOSE rhuMAb Beta7 is a humanized anti-human β7 monoclonal antibody currently in phase I in inflammatory bowel disease. rhuMAb Beta7 binds the β7 subunit of the integrins α4β7 and αEβ7, blocking interaction with their ligands.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17a3ee5a0973e8f22668d027c1912e05
https://doi.org/10.1111/j.1476-5381.2011.01205.x
https://doi.org/10.1111/j.1476-5381.2011.01205.x
Autor:
Jean F. Colombel, Javaria Mona Khalid, Severine Vermeire, Silvio Danese, Arthur Kaser, Geert R. D'Haens, Edward V. Loftus, Brian G. Feagan, Parnia Geransar, Alessandro Previtali, Arpeat Kaviya, Sharon O'Byrne, William J. Sandborn, Ira Shafran, Remo Panaccione, David T. Rubin, Bruce E. Sands
Publikováno v:
ResearcherID
Introduction Vedolizumab (VDZ), a gut-selective humanised monoclonal antibody that targets α4β7 integrin, is approved for moderately to severely active Crohn’s disease and ulcerative colitis (UC). The ongoing GEMINI open-label extension (OLE) tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::066f3fd052bb30a367a38cd073bce297
https://doi.org/10.1016/s0016-5085(17)32147-9
https://doi.org/10.1016/s0016-5085(17)32147-9
Autor:
Javaria Mona Khalid, William J. Sandborn, David T. Rubin, Parnia Geransar, Sharon O'Byrne, Brian G. Feagan, Jean-Frederic Colombel, Nigel Brayshaw
Publikováno v:
Gastroenterology. 152:S597
Introduction Reported rates of extraintestinal manifestations (EIMs) in patients (pts) with Crohn’s disease (CD) are 37%–55%. 1,2 This post hoc exploratory analysis investigated the effect of vedolizumab (VDZ) treatment on existing and new EIMs i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cddf63b635e3621c583fc0503288baad
https://doi.org/10.1016/s0016-5085(17)32137-6
https://doi.org/10.1016/s0016-5085(17)32137-6